184 related articles for article (PubMed ID: 35155791)
1. Gene expression profiling for metastatic risk in head and neck cutaneous squamous cell carcinoma.
Arron ST; Wysong A; Hall MA; Bailey CN; Covington KR; Kurley SJ; Goldberg MS; Kasprzak JM; Somani AK; Ibrahim SF; Brodland DG; Cleaver NJ; Maher IA; Xia Y; Koyfman SA; Newman JG
Laryngoscope Investig Otolaryngol; 2022 Feb; 7(1):135-144. PubMed ID: 35155791
[TBL] [Abstract][Full Text] [Related]
2. The Prognostic Value and Clinical Utility of the 40-Gene Expression Profile (40-GEP) Test in Cutaneous Squamous Cell Carcinoma: Systematic Review and Meta-Analysis.
Masarwy R; Shilo S; Carmel Neiderman NN; Kampel L; Horowitz G; Muhanna N; Mansour J
Cancers (Basel); 2023 Apr; 15(9):. PubMed ID: 37173922
[TBL] [Abstract][Full Text] [Related]
3. Integrating the 40-Gene Expression Profile (40-GEP) Test Improves Metastatic Risk-Stratification Within Clinically Relevant Subgroups of High-Risk Cutaneous Squamous Cell Carcinoma (cSCC) Patients.
Wysong A; Somani AK; Ibrahim SF; Cañueto J; Fitzgerald AL; Siegel JJ; Prasai A; Goldberg MS; Farberg AS; Regula C; Bar A; Kasprzak J; Brodland DG; Koyfman SA; Arron ST
Dermatol Ther (Heidelb); 2024 Mar; 14(3):593-612. PubMed ID: 38424384
[TBL] [Abstract][Full Text] [Related]
4. Validation of a 40-gene expression profile test to predict metastatic risk in localized high-risk cutaneous squamous cell carcinoma.
Wysong A; Newman JG; Covington KR; Kurley SJ; Ibrahim SF; Farberg AS; Bar A; Cleaver NJ; Somani AK; Panther D; Brodland DG; Zitelli J; Toyohara J; Maher IA; Xia Y; Bibee K; Griego R; Rigel DS; Meldi Plasseraud K; Estrada S; Sholl LM; Johnson C; Cook RW; Schmults CD; Arron ST
J Am Acad Dermatol; 2021 Feb; 84(2):361-369. PubMed ID: 32344066
[TBL] [Abstract][Full Text] [Related]
5. Association of a 40-Gene Expression Profile With Risk of Metastatic Disease Progression of Cutaneous Squamous Cell Carcinoma (cSCC) and Specification of Benefit of Adjuvant Radiation Therapy.
Arron ST; Cañueto J; Siegel J; Fitzgerald A; Prasai A; Koyfman SA; Yom SS
Int J Radiat Oncol Biol Phys; 2024 May; ():. PubMed ID: 38810706
[TBL] [Abstract][Full Text] [Related]
6. Integrating gene expression profiling into NCCN high-risk cutaneous squamous cell carcinoma management recommendations: impact on patient management.
Farberg AS; Hall MA; Douglas L; Covington KR; Kurley SJ; Cook RW; Dinehart SM
Curr Med Res Opin; 2020 Aug; 36(8):1301-1307. PubMed ID: 32351136
[No Abstract] [Full Text] [Related]
7. Clinical Utility of the 40-Gene Expression Profile (40-GEP) Test for Improved Patient Management Decisions and Disease-Related Outcomes when Combined with Current Clinicopathological Risk Factors for Cutaneous Squamous Cell Carcinoma (cSCC): Case Series.
Au JH; Hooper PB; Fitzgerald AL; Somani AK
Dermatol Ther (Heidelb); 2022 Feb; 12(2):591-597. PubMed ID: 34951694
[TBL] [Abstract][Full Text] [Related]
8. Integrating 40-GEP Testing to Improve Clinical Recommendations for Adjuvant Radiation for Cutaneous Squamous Cell Carcinoma: Multidisciplinary Consensus Guidelines.
Gopal R; Marquardt M; Singh G; Tolkachjov SN; Arron ST
J Clin Aesthet Dermatol; 2024 Mar; 17(3 Suppl 2):S3-S8. PubMed ID: 38495846
[TBL] [Abstract][Full Text] [Related]
9. Incorporation of the 40-Gene Expression Profile (40-GEP) Test to Improve Treatment Decisions in High-Risk Cutaneous Squamous Cell Carcinoma (cSCC) Patients: Case Series and Algorithm.
Singh G; Tolkachjov SN; Farberg AS
Clin Cosmet Investig Dermatol; 2023; 16():925-935. PubMed ID: 37051586
[TBL] [Abstract][Full Text] [Related]
10. Impact of Gene Expression Profile Testing on the Management of Squamous Cell Carcinoma by Dermatologists.
Rebeca T; Giselle P; Litchman GH; Rigel DS
J Drugs Dermatol; 2019 Oct; 18(10):980-984. PubMed ID: 31584775
[TBL] [Abstract][Full Text] [Related]
11. Enhanced metastatic risk assessment in cutaneous squamous cell carcinoma with the 40-gene expression profile test.
Ibrahim SF; Kasprzak JM; Hall MA; Fitzgerald AL; Siegel JJ; Kurley SJ; Covington KR; Goldberg MS; Farberg AS; Trotter SC; Reed K; Brodland DG; Koyfman SA; Somani AK; Arron ST; Wysong A
Future Oncol; 2022 Mar; 18(7):833-847. PubMed ID: 34821148
[TBL] [Abstract][Full Text] [Related]
12. 40-Gene Expression Profile Representative of Metastatic Risk of Squamous Cell Carcinoma in a Mohs Surgical Patient.
Slater KN; Ryder E; Gomez-Meade C
Cureus; 2023 Oct; 15(10):e46853. PubMed ID: 37954812
[TBL] [Abstract][Full Text] [Related]
13. Impact of a prognostic 40-gene expression profiling test on clinical management decisions for high-risk cutaneous squamous cell carcinoma.
Litchman GH; Fitzgerald AL; Kurley SJ; Cook RW; Rigel DS
Curr Med Res Opin; 2020 Aug; 36(8):1295-1300. PubMed ID: 32372702
[No Abstract] [Full Text] [Related]
14. Validating 4 Staging Systems for Cutaneous Squamous Cell Carcinoma Using Population-Based Data: A Nested Case-Control Study.
Roscher I; Falk RS; Vos L; Clausen OPF; Helsing P; Gjersvik P; Robsahm TE
JAMA Dermatol; 2018 Apr; 154(4):428-434. PubMed ID: 29516080
[TBL] [Abstract][Full Text] [Related]
15. Validation of four cutaneous squamous cell carcinoma staging systems using nationwide data.
Venables ZC; Tokez S; Hollestein LM; Mooyaart AL; van den Bos RR; Rous B; Leigh IM; Nijsten T; Wakkee M
Br J Dermatol; 2022 May; 186(5):835-842. PubMed ID: 34862598
[TBL] [Abstract][Full Text] [Related]
16. Personalised decision making to predict absolute metastatic risk in cutaneous squamous cell carcinoma: development and validation of a clinico-pathological model.
Rentroia-Pacheco B; Tokez S; Bramer EM; Venables ZC; van de Werken HJG; Bellomo D; van Klaveren D; Mooyaart AL; Hollestein LM; Wakkee M
EClinicalMedicine; 2023 Sep; 63():102150. PubMed ID: 37662519
[TBL] [Abstract][Full Text] [Related]
17. Real-World Evidence Shows Clinicians Appropriately Use the Prognostic 40-Gene Expression Profile (40-GEP) Test for High-Risk Cutaneous Squamous Cell Carcinoma (cSCC) Patients.
Hooper PB; Farberg AS; Fitzgerald AL; Siegel JJ; Rackley BB; Prasai A; Kurley SJ; Goldberg MS; Litchman GH
Cancer Invest; 2022 Nov; 40(10):911-922. PubMed ID: 36073945
[TBL] [Abstract][Full Text] [Related]
18. Analysis of selected risk factors for nodal metastases in head and neck cutaneous squamous cell carcinoma.
Szewczyk M; Pazdrowski J; Golusiński P; Dańczak-Pazdrowska A; Marszałek S; Golusiński W
Eur Arch Otorhinolaryngol; 2015 Oct; 272(10):3007-12. PubMed ID: 25217080
[TBL] [Abstract][Full Text] [Related]
19. Improved cutaneous melanoma survival stratification through integration of 31-gene expression profile testing with the American Joint Committee on Cancer 8th Edition Staging.
Wisco OJ; Marson JW; Litchman GH; Brownstone N; Covington KR; Martin BJ; Quick AP; Siegel JJ; Caruso HG; Cook RW; Winkelmann RR; Rigel DS
Melanoma Res; 2022 Apr; 32(2):98-102. PubMed ID: 35254332
[TBL] [Abstract][Full Text] [Related]
20. Comparison of tumor staging systems for cutaneous squamous cell carcinoma in patients with chronic lymphocytic leukemia.
Inda JJ; Kabat BF; Larson MC; Slager SL; Baum CL
J Am Acad Dermatol; 2019 Mar; 80(3):639-645. PubMed ID: 30165169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
